ATAI
Atai Beckley N.V NASDAQ Listed Jun 18, 2021$4.01
Mkt Cap $756.4M
52w Low $1.29
49.8% of range
52w High $6.75
50d MA $3.89
200d MA $4.28
P/E (TTM)
-1.4x
EV/EBITDA
-7.5x
P/B
4.2x
Debt/Equity
0.0x
ROE
-297.5%
P/FCF
-8.9x
RSI (14)
—
ATR (14)
—
Beta
1.57
50d MA
$3.89
200d MA
$4.28
Avg Volume
5.7M
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Prof. J.H. Bavincklaan 7 · Amstelveen, NY 1183 AT · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | AMC | -0.12 | -0.05 | +58.3% | 3.39 | +0.3% | +14.7% | +22.1% | +19.8% | +12.7% | +8.8% | — |
| Nov 12, 2025 | AMC | -0.12 | -0.28 | -133.3% | 4.33 | -1.4% | -4.6% | -7.6% | -8.5% | -9.2% | -11.8% | — |
| Aug 14, 2025 | AMC | -0.12 | -0.14 | -16.7% | 4.01 | -1.5% | -3.2% | +1.0% | -1.0% | -1.0% | +9.5% | — |
| May 14, 2025 | AMC | -0.19 | -0.15 | +21.1% | 1.43 | +0.0% | +14.0% | +15.4% | +28.7% | +43.4% | +33.6% | — |
| Mar 17, 2025 | AMC | -0.14 | -0.24 | -71.4% | 1.46 | -2.7% | -7.5% | -4.8% | -6.2% | -0.7% | +7.5% | — |
| Nov 13, 2024 | AMC | -0.15 | -0.16 | -6.7% | 1.35 | +3.0% | +1.5% | +19.3% | +23.7% | +28.1% | +17.8% | — |
| Aug 13, 2024 | AMC | -0.17 | -0.36 | -111.8% | 1.22 | +0.0% | -4.1% | +2.5% | +0.0% | +7.4% | +7.4% | — |
| May 15, 2024 | AMC | -0.20 | -0.17 | +15.0% | 2.05 | +0.5% | -9.3% | -16.6% | -15.6% | -18.0% | -18.5% | — |
| Mar 28, 2024 | AMC | -0.17 | -0.12 | +29.4% | 1.97 | +0.0% | -5.6% | -5.1% | +21.3% | +27.4% | +24.4% | — |
| Nov 14, 2023 | AMC | -0.20 | -0.14 | +30.0% | 1.25 | +2.0% | -4.4% | -11.6% | -11.6% | -10.8% | -14.7% | — |
| Aug 10, 2023 | AMC | -0.21 | -0.21 | +0.0% | 1.71 | +0.6% | -1.8% | -2.9% | -5.8% | -2.3% | -7.0% | — |
| May 11, 2023 | AMC | -0.22 | -0.21 | +4.5% | 1.96 | +1.0% | -3.1% | +2.0% | -1.0% | -3.1% | -5.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.03 | $5.03 | +24.8% | +21.6% | +20.8% | +16.9% | +18.4% | +14.9% |
| Apr 17 | Guggenheim | Maintains | Buy → Buy | — | $4.09 | $4.19 | +2.4% | -1.5% | +19.8% | +19.1% | +15.2% | +16.6% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.70 | +1.4% | +0.0% | -2.5% | -2.2% | -4.4% | -7.1% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $3.39 | $3.40 | +0.3% | +14.7% | +22.1% | +19.8% | +12.7% | +8.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.50 | -3.6% | +1.4% | +1.7% | +1.7% | -2.5% | -6.6% |
| Oct 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.87 | $5.95 | +1.4% | -3.9% | -5.5% | -1.7% | +6.0% | +1.5% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $5.11 | +4.7% | +15.0% | +12.5% | +5.9% | +8.0% | +11.7% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.31 | $3.39 | +2.4% | +4.8% | +23.9% | +26.0% | +28.7% | +25.1% |
| Jul 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.57 | $3.13 | -12.3% | -6.7% | -7.3% | -2.8% | +14.8% | +16.8% |
| Jul 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.71 | $2.96 | +9.2% | +1.5% | +2.2% | +1.5% | -3.0% | -1.8% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.84 | $1.83 | -0.5% | +11.4% | +3.8% | +9.8% | +12.0% | +20.1% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.36 | +0.7% | +3.0% | +1.5% | +7.4% | +16.3% | +16.3% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.28 | -10.6% | -11.0% | -9.8% | -18.8% | -18.0% | -20.0% |
| Nov 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.61 | $1.65 | +2.5% | +3.7% | +7.5% | -1.2% | -5.6% | +0.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.61 | $1.65 | +2.5% | +3.7% | +7.5% | -1.2% | -5.6% | +0.0% |
No insider trades available.
8-K · 1.01
! Medium
AtaiBeckley Inc. -- 8-K 1.01: Equity Issuance
Atai Beckley Inc. (ATAI) established an open market sale agreement with Jefferies LLC, enabling the company to conduct at-the-market equity offerings for capital raising purposes.
Mar 9
8-K · 7.01
! Medium
AtaiBeckley Inc. -- 8-K 7.01: Regulation FD Disclosure
ATAI is hosting a virtual investor day on March 6, 2026, featuring executive presentations and Q&A sessions with KOLs to discuss company strategy and outlook.
Mar 6
8-K · 8.01
!! High
AtaiBeckley Inc. -- 8-K 8.01: Material Event / Announcement
ATAI completed its acquisition of the remaining stake in Beckley Psytech, consolidating full ownership of the psychedelic research company and strengthening its portfolio of mental health therapeutics.
Mar 6
8-K · 7.01
! Medium
AtaiBeckley Inc. -- 8-K 7.01: Regulation FD Disclosure
AtaiBeckley announced positive Phase 2a results for EMP-01, an oral MDMA treatment for social anxiety disorder, potentially validating its psychedelic therapeutic development pipeline.
Feb 26
8-K · 5.02
!!! Very High
AtaiBeckley Inc. -- 8-K 5.02: Executive Change
AtaiBiomedicines appointed Michael Faerm as CFO and principal accounting officer, strengthening financial leadership amid the company's clinical development programs.
Feb 19
Data updated apr 24, 2026 7:26pm
· Source: massive.com